Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 4/2019

01-12-2019 | Original Research

Radio-pathological Correlation of 18F-FDG PET in Characterizing Gallbladder Wall Thickening

Authors: Vikas Gupta, K. S. Vishnu, Thakur D. Yadav, Yashwant R. Sakaray, Santosh Irrinki, B. R. Mittal, N. Kalra, K. Vaiphei

Published in: Journal of Gastrointestinal Cancer | Issue 4/2019

Login to get access

Abstract

Aim

Thick-walled gallbladder is difficult to characterize on conventional imaging. 18F-FDG PET was used to differentiate benign and malignant wall thickness and compared with histopathology.

Methods

Thirty patients with gallbladder (GB) wall thickening (focal > 4 mm and diffuse > 7 mm), underwents uspected on  ultrasound, or CT scan, and underwent 18F-FDG PET. Histopathology of the specimen was compared with imaging findings.

Results

The mean age was 48.22 ± 31.33 years with a M:F 1:4 ratio. Twenty patients had diffuse and 10 had focal thickening. On 18F-FDG PET, lesion was benign in 12, malignant in 13, and indeterminate in 5. Histopathology was malignancy in 12; benign in 18-chronic cholecystitis in 11, xanthogranulomatous in 4, IgG4 related in 2, and polyp in 1. The mean GB wall thickness was 7.79 ± 3.59 mm (10.34 malignant and 6.10 in benign, p = 0.001). At a cutoff of 8.5 mm, the sensitivity and specificity of detecting malignancy was 94% and 67%. The mean SUV uptake was 7.46 (benign 4.51, malignant 14.26, p = 0.0102). At a cutoff of 5.95, the sensitivity and specificity of detecting malignancy was 92% and 79%. For 18F-FDG PET, overall sensitivity was 91%, specificity 79%, PPV 77%, NPV 92%, and diagnostic accuracy was 84%.

Conclusion

18F-FDG PET is a reliable method of differentiation between benign and malignant thickening of the gallbladder particularly when wall thickness and SUV value is taken into account.
Literature
1.
go back to reference Malhotra RK, Manoharan N, Shukla NK, Rath GK. Gallbladder cancer incidence in Delhi urban: a 25-year trend analysis. Ind J Cancer. 2017;54:673–7.CrossRef Malhotra RK, Manoharan N, Shukla NK, Rath GK. Gallbladder cancer incidence in Delhi urban: a 25-year trend analysis. Ind J Cancer. 2017;54:673–7.CrossRef
2.
go back to reference Köhn N, Maubach J, Warschkow R, Tsai C, Nussbaum DP, Candinas D, et al. High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. HPB (Oxford). 2018 Jun 8 S1365-182X(18)30819-0. https://doi.org/10.1016/j.hpb.2018.05.007. Köhn N, Maubach J, Warschkow R, Tsai C, Nussbaum DP, Candinas D, et al. High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. HPB (Oxford). 2018 Jun 8 S1365-182X(18)30819-0. https://​doi.​org/​10.​1016/​j.​hpb.​2018.​05.​007.
3.
go back to reference Goussous N, Maqsood H, Patel K, Ferdosi H, Muhammad N, Sill AM, et al. Clues to predict incidental gallbladder cancer. Hepatobiliary Pancreat Dis Int. 2018;17:149–57.CrossRef Goussous N, Maqsood H, Patel K, Ferdosi H, Muhammad N, Sill AM, et al. Clues to predict incidental gallbladder cancer. Hepatobiliary Pancreat Dis Int. 2018;17:149–57.CrossRef
4.
go back to reference Mitchell CH, Johnson PT, Fishman EK, Hruban RH, Raman SP. Features suggestive of gallbladder malignancy: analysis of T1, T2, and T3 tumors on cross-sectional imaging. J Comput Assist Tomogr. 2014;38:235–41.CrossRef Mitchell CH, Johnson PT, Fishman EK, Hruban RH, Raman SP. Features suggestive of gallbladder malignancy: analysis of T1, T2, and T3 tumors on cross-sectional imaging. J Comput Assist Tomogr. 2014;38:235–41.CrossRef
5.
go back to reference Wasnik AP, Davenport MS, Kaza RK, Weadock WJ, Udager A, Keshavarzi N, et al. Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis. Clin Imag. 2018;50:223–8.CrossRef Wasnik AP, Davenport MS, Kaza RK, Weadock WJ, Udager A, Keshavarzi N, et al. Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis. Clin Imag. 2018;50:223–8.CrossRef
7.
go back to reference Kishore R, Nundy S, Mehrotra S, Mehta N, Mangla V, Lalwani S. Strategies for differentiating gallbladder carcinoma from xanthogranuomatous cholecystitis – a tertiary care centre experience. Ind J Surg Oncol. 2017;8:554–9.CrossRef Kishore R, Nundy S, Mehrotra S, Mehta N, Mangla V, Lalwani S. Strategies for differentiating gallbladder carcinoma from xanthogranuomatous cholecystitis – a tertiary care centre experience. Ind J Surg Oncol. 2017;8:554–9.CrossRef
8.
go back to reference Rao RV, Kumar A, Sikora SS, Saxena R, Kapoor VK. Xanthogranulomatous cholecystitis: differentiation from associated gall bladder carcinoma. Trop Gastroenterol. 2005;26:31–3.PubMed Rao RV, Kumar A, Sikora SS, Saxena R, Kapoor VK. Xanthogranulomatous cholecystitis: differentiation from associated gall bladder carcinoma. Trop Gastroenterol. 2005;26:31–3.PubMed
9.
go back to reference Kim SJ, Lee JM, Lee JY, Kim SH, Han JK, Choi BI, et al. Analysis of enhancement pattern of flat gallbladder wall thickening on MDCT to differentiate gallbladder cancer from cholecystitis. Am J Roentgenol. 2008;191:765–71.CrossRef Kim SJ, Lee JM, Lee JY, Kim SH, Han JK, Choi BI, et al. Analysis of enhancement pattern of flat gallbladder wall thickening on MDCT to differentiate gallbladder cancer from cholecystitis. Am J Roentgenol. 2008;191:765–71.CrossRef
10.
go back to reference Sureka B, Singh VP, Rajesh SR, Laroia S, Bansa K, Rastogi A, et al. Computed tomography (CT) and magnetic resonance (MR) findings in xanthogranulomatous cholecystitis: retrospective analysis of pathologically proven 30 cases – tertiary care experience. Pol J Radiol. 2017;82:327–32.CrossRef Sureka B, Singh VP, Rajesh SR, Laroia S, Bansa K, Rastogi A, et al. Computed tomography (CT) and magnetic resonance (MR) findings in xanthogranulomatous cholecystitis: retrospective analysis of pathologically proven 30 cases – tertiary care experience. Pol J Radiol. 2017;82:327–32.CrossRef
11.
go back to reference Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol. 2011;197:260–5.CrossRef Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol. 2011;197:260–5.CrossRef
12.
go back to reference Covera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18 F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2007;206:57–65.CrossRef Covera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18 F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2007;206:57–65.CrossRef
13.
go back to reference Annunziata S, Pizzuto AP, Caldarella C, Galiandro F, sadeghi R, Treglia G. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in gallbladder cancer: a meta-analysis. World J Gastroenterol. 2015;21:11481–8.CrossRef Annunziata S, Pizzuto AP, Caldarella C, Galiandro F, sadeghi R, Treglia G. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in gallbladder cancer: a meta-analysis. World J Gastroenterol. 2015;21:11481–8.CrossRef
14.
go back to reference Oe A, Kawabe J, Toril K, Higashiyama S, Kotani J, Hayashi T, et al. Distinguishing between benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med. 2006;20:699–703.CrossRef Oe A, Kawabe J, Toril K, Higashiyama S, Kotani J, Hayashi T, et al. Distinguishing between benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med. 2006;20:699–703.CrossRef
15.
go back to reference Roms-Font C, Gomez-Rio M, Rodriguez-Fernandez A, Jimenez-Haffernan A, Sanchez RS, Llamas-Elvira JM. Ability of FDG-PET/CT in the detection of gallbladder cancer. J Surg Oncol. 2014;109:218–24.CrossRef Roms-Font C, Gomez-Rio M, Rodriguez-Fernandez A, Jimenez-Haffernan A, Sanchez RS, Llamas-Elvira JM. Ability of FDG-PET/CT in the detection of gallbladder cancer. J Surg Oncol. 2014;109:218–24.CrossRef
16.
go back to reference Anderson CD, Rice MH, Pinson W, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose pet imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8:90–7.CrossRef Anderson CD, Rice MH, Pinson W, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose pet imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8:90–7.CrossRef
17.
go back to reference Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, et al. Dual-time –point 18F-FDG PET for evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633–8.PubMed Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, et al. Dual-time –point 18F-FDG PET for evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633–8.PubMed
18.
go back to reference Jindal G, Singal S, Nagi B, Mittal A, Mittal S, Singal R. Role of multidetector computed tomography (MDCT) in evaluation of gallbladder malignancy and its pathological correlation in an indian rural center. Maedica – J Clin Med. 2018;13:55–60.CrossRef Jindal G, Singal S, Nagi B, Mittal A, Mittal S, Singal R. Role of multidetector computed tomography (MDCT) in evaluation of gallbladder malignancy and its pathological correlation in an indian rural center. Maedica – J Clin Med. 2018;13:55–60.CrossRef
19.
go back to reference Hwang JP, Lim I, Cho EH, Kim BI, Choi CW, Lim SM. Prognostic value of SUV max measured by Fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography in patients with gallbladder cancer. Nucl Med Mol Imag. 2014;48:114–20.CrossRef Hwang JP, Lim I, Cho EH, Kim BI, Choi CW, Lim SM. Prognostic value of SUV max measured by Fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography in patients with gallbladder cancer. Nucl Med Mol Imag. 2014;48:114–20.CrossRef
20.
go back to reference Koh T, Taniguchi H, Yamaguchi A, Kunishima S, Yamagishi H. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol. 2003;84:74–81.CrossRef Koh T, Taniguchi H, Yamaguchi A, Kunishima S, Yamagishi H. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol. 2003;84:74–81.CrossRef
21.
go back to reference Furukawa H, Ikuma H, Assakura K, Uesaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009;100:494–9.CrossRef Furukawa H, Ikuma H, Assakura K, Uesaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009;100:494–9.CrossRef
22.
go back to reference Rodriguez-Fernandez A, Gomez-Rio M, Llamas-Elvira JM, Ortega-Lozano S, Ferron-Orihuela JA, Ramia-Angel JM, et al. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-Dglucose for gallbladder cancer diagnosis. Am J Surg. 2004;188:171–5.CrossRef Rodriguez-Fernandez A, Gomez-Rio M, Llamas-Elvira JM, Ortega-Lozano S, Ferron-Orihuela JA, Ramia-Angel JM, et al. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-Dglucose for gallbladder cancer diagnosis. Am J Surg. 2004;188:171–5.CrossRef
Metadata
Title
Radio-pathological Correlation of 18F-FDG PET in Characterizing Gallbladder Wall Thickening
Authors
Vikas Gupta
K. S. Vishnu
Thakur D. Yadav
Yashwant R. Sakaray
Santosh Irrinki
B. R. Mittal
N. Kalra
K. Vaiphei
Publication date
01-12-2019
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 4/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-018-0176-2

Other articles of this Issue 4/2019

Journal of Gastrointestinal Cancer 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.